

Universal Biosensors, Inc.  
ARBN 121 559 993

1 Corporate Avenue  
Rowville Victoria 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



14 September 2021

## **Peter MacCallum Cancer Centre : Tn Antigen cancer biosensor trial**

Universal Biosensors, Inc. (ASX:UBI) is pleased to announce it has entered into an agreement with the Peter MacCallum Cancer Centre (Peter Mac) to supply cancer patient samples which will be used to develop and validate the performance of UBI's handheld point-of-care cancer biosensor for Tn Antigen (Tn).

This agreement provides UBI with access to plasma samples collected from patients with colorectal, breast and prostate cancer as part of a Peter Mac research initiative. Trial results will be used to confirm the presence of Tn in multiple cancer types and determine the clinically relevant range of Tn concentrations.

The trial is scheduled to commence during October and results should be available during Q1 2022.

UBI's objective is for the handheld Tn biosensor to accurately measure a patient's cancer status (monitoring of remission and reoccurrence) in easier, cheaper and more frequent tests.

John Sharman, CEO of UBI said, "To be working with Peter Mac on the development of UBI's handheld point-of-care cancer biosensor is very exciting for the Company. The trial results and any subsequent development work, will form part of any regulatory application to have Tn approved for sale by regulators around the world (project timelines detailed below)."

Mr Sharman said, "The blood testing market for cancer remission patients globally is AUD \$17 billion per annum. Potentially the Tn biosensor may be used for early cancer diagnosis, disease staging and monitoring of treatment effectiveness."

**End**

Enquiries:

John Sharman


Chief Executive Officer

+61 (0) 414 440 680

**Announcement authorised by the Board of Directors of Universal Biosensors, Inc.**

## Project timelines

### Tn Antigen



### About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. Our wine testing platform Sentia is UBI's newest product which is being launched globally. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

### About Peter MacCallum Cancer Centre

Peter MacCallum Cancer Centre is a world leading cancer research, education and treatment centre and Australia's only public health service solely dedicated to caring for people affected by cancer. We have over 3,200 staff, including more than 700 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.

### Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.